Skip to content

Latest commit

 

History

History
19 lines (13 loc) · 1.66 KB

README.md

File metadata and controls

19 lines (13 loc) · 1.66 KB
Raw

Ruxolitinib-Model

Ruxolitinib PBPK

Repository files

Within this repository we share a whole body PBPK model of Ruxolitinib to model drug-drug-interactions (DDI) via CYP3A4.

For a detailed documentation of model development, quantitative model evaluation and sensitivity analysis, please refer to [1].

Code of conduct

Everyone interacting in the Open Systems Pharmacology community (codebases, issue trackers, chat rooms, mailing lists etc...) is expected to follow the Open Systems Pharmacology code of conduct.

Contribution

We encourage contribution to the Open Systems Pharmacology community. Before getting started please read the contribution guidelines. If you are contributing code, please be familiar with the coding standard.

License

The model code is distributed under the GPLv2 License.

References

[1] Gerner, B.; Aghai-Trommelschlaeger, F.; Kraus, S.; Grigoleit, G.U.; Zimmermann, S.; Kurlbaum, M.; Klinker, H.; Isberner, N.; Scherf-Clavel, O. A Physiologically-Based Pharmacokinetic Model of Ruxolitinib and Posaconazole to Predict CYP3A4-Mediated Drug-Drug Interaction Frequently Observed in Graft versus Host Disease Patients Pharmaceutics 2022, 14(12), 2556.